We conducted a 78-week randomized, open-label, treat-to-target phase 3a trial (including a 52-week main phase and a 26-week extension phase, plus a 5-week follow-up period) involving adults with type ...

SAN DIEGO -- Investigational once-weekly insulin icodec outperformed once-daily insulin glargine U100 when it came to glycemic control in type 2 diabetes, the phase IIIa ONWARDS 1 trial found. Over ...

It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin ...

Insulin icodec, a once-weekly basal injection to treat type 1 diabetes, has the potential to be as effective in managing the condition as daily basal insulin treatments, according to new research. The ...

For patients with insulin-naive type 2 diabetes, once-weekly icodec is superior for reduction in hemoglobin A1c (HbA1c), according to a study published online June 24 in the Journal of the American ...

In the Phase 3a ONWARDS 5 randomized trial, once-weekly insulin icodec titrated with a dosing guide app demonstrated superior reduction in HbA1c levels and similarly low hypoglycemia rates compared ...

A novel insulin formulation given once weekly was as safe and effective as a conventional daily insulin product for type 2 diabetes, a randomized, placebo-controlled phase II trial showed. Compared ...

STOCKHOLM, Sweden — The investigational once-weekly insulin icodec (Novo Nordisk) significantly reduces A1c without increasing hypoglycemia in people with type 2 diabetes, the first Phase 3 data of ...